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Objective: Our aim was to investigate the relationships between serum periostin (POSTN) and both
prevalence and incidence/progression of knee osteoarthritis (OA) in women.
Methods: We investigated 594 women (62.7 ± 11.2 yr) from the OFELY cohort. Knee radiographs were
scored according to the Kellgren & Lawrence (KL) grading system at baseline and 4 years later. Spine, hip
and hand OAwere assessed at baseline. Prevalent knee OAwas deﬁned by a KL score higher or equal in 2.
Progression of KL was deﬁned as an increase of the KL score 1 during the 4 years follow-up. Serum
POSTN was measured at baseline by ELISA.
Results: By non-parametric tests, POSTN was signiﬁcantly lower in 83 women with a KL score 2 at
baseline, compared to those with a KL score <2 (n ¼ 511; 1101 ± 300 vs 1181 ± 294 ng/ml, P ¼ 0.002)
after adjustment for age, body mass index (BMI), treatments and diseases, prevalent hand OA and
prevalent lumbar spine OA. By logistic regression analyses, the odds-ratio of knee OA incidence/pro-
gression was signiﬁcantly reduced by 21% (P ¼ 0.043) for each quartile increase in serum POSTN at
baseline, after adjustment for age, BMI, prevalent knee OA, prevalent hand OA and prevalent lumbar
spine OA.
Conclusions: We show for the ﬁrst time that serum POSTN is associated with prevalence and the risk of
development/progression of knee OA in women.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is themost frequent chronic musculoskeletal
disease affecting approximately 40% of adults aged 70 years and
over1. It is considered as a slowly progressive disease deteriorating
all tissues of the affected joint and appearing as a degradation of
cartilage, the hallmark of OA, but also a mild-to-moderate synovial
inﬂammation and an impairment of subchondral bone structure2e5.
One of the most important metabolic pathways regulating bone
and cartilage homeostasis in adults is the Wnt-b-catenin signalling
pathway6e8. Several lines of evidence showed that Wnt-b-catenin
is involved in the OA process although animal models and data on: J.C. Rousseau, INSERM Unit
03, France. Tel: 33-4-72-11-
fr (J.C. Rousseau), elisabeth.
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ternational. Published by Elsevier Lthe association of circulating inhibitors of this pathway in human
OA have generated conﬂicting results9. We have speculated that the
measurement of stimulators of the Wnt-b-signaling pathway could
bring valuable information concerning the implication of Wnt-b-
catenin signalling in OA. Among them, periostin (POSTN) appears
as a potential candidate. Indeed, two studies in rats and in human
subjects10e12 found that the POSTN gene is signiﬁcantly upregu-
lated in the subchondral bone during OA disease. POSTN is a
matricellular protein expressed predominantly in the periosteum
which covers a large majority of bones13,14 but also in the cartilage
matrix by the chondrocytes15. It is an important mediator of the
effects of mechanical factors and PTH on BMD, bone strength and
fracture pathogenesis16. Because POSTN is a secreted soluble factor,
a speciﬁc immunoassay has been recently developed to measure its
concentration in serum and plasma. Serum POSTN has been
investigated mainly in the context of oncogenesis17. To our best
knowledge, there is no published study that has investigated the
relationships between serum POSTN and OA. Consequently, the
main objective of this study was to investigate the relationshiptd. All rights reserved.
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assay and prevalence and incidence/progression of knee OA in
women. We also studied the relationship between POSTN and CTX-
II, one of the most efﬁcient prognostic marker of knee OA18.
Materials and methods
Patients
The study group included French women belonging to a
population-based cohort. These women were participants in a
prospective investigation of the determinants of bone loss, the Os
des FEmmes de LYon (OFELY) study. This cohort has previously
been described in details elsewhere19. In the present analysis, we
studied a group of 594 women, who had both serum POSTN and
urinary CTX-II measurements, and an evaluation of OA disease by
radiography for spine disc degeneration and knee OA, by clinical
examination for the hand OA and by a questionnaire for the hip
OA. These evaluations have been performed at the same visit, 8
years after the recruitment of the cohort (ninth follow-up visit).
After baseline OA assessment, women were followed prospectively
for 4 years.
Assessment of knee OA
Radiographs of both knees were obtained in all women.
Radiologic evaluation of the knees consisted of bilateral postero-
anterior weight-bearing knee radiographs with ﬁxed ﬂexion us-
ing the SynaFlex X-ray Positioning Frame (Synarc, San Francisco,
CA), as previously described20. Radiographs were obtained in a
single radiography unit by the same staff of 2 technicians using a
previously described standardized protocol21. The severity of OA
was performed and graded according to the Kellgren & Lawrence
(KL) at baseline and 4 years later22. Prevalent knee OA was deﬁned
by a KL score higher or equal in 2 at baseline. Incident OA was
deﬁned by a KL score higher or equal in 2 at year 4 and a KL score<2
at baseline. Progressors were women with a KL score at year 4
strictly higher than the KL score at baseline. All knee radiographs
were scored by a single trained rheumatologist (ES-R). Measure-
ments were made paired but not blinded to sequence, which has
been shown not to modify the sensitivity to change23.
Assessment of lumbar spine OA
At baseline, lateral radiographs of the spine were available and
interpretable in 421 women (age 50 years and older at the
recruitment of the cohort). Spine ﬁlmswere gradedwith a standard
atlas to document the severity of disc space narrowing (DSN) and
osteophyte (OPH) formation, using the grading system described by
Lane et al.24 with a 4-point scale: normal 0, mild 1, moderate 2, and
severe 3. Then, a grade was deﬁned as 0 if both scores were normal,
1 if therewasmild OPH or DSN, or 2 if therewasmoderate or severe
OPH or DSN. Lumbar OA was assessed at 4 levels from L1eL2 to
L4eL5. Lumbar OA was deﬁned with the highest score of OPH and
DSN and with the highest grade among the four levels. In our study,
womenwere considered as having a spine OAwhen the ﬁnal grade
at baseline was higher or equal in 1. All spine radiographs were
scored by a single trained rheumatologist (ES-R)25.
Assessment of clinical hand OA
Clinical hand OA was assessed by a trained rheumatologist who
systematically evaluated each hand in all subjects for Heberden's
nodes of the distal interphalangeal joints, Bouchard's nodes of the
proximal interphalangeal joints, and swelling of the ﬁrstcarpometacarpal joint. The presence of hand OA was deﬁned ac-
cording to the American College of Rheumatology criteria26.
Assessment of hip OA
Hip OA was self-reported. Women from the OFELY cohort
answered to the following question: “Has a doctor ever told you
that you had hip osteoarthritis?” Subjects who answered “yes” to
this questionwere considered as having a hip OA only if the general
practitioner had detected the hip OA on radiographs of the affected
hip.
Biochemistry
Blood samples were collected between 8:00 and 9:30 a.m. after
an overnight fast at the ninth annual follow-up visit (baseline visit
of the current analysis). Serum samples were stored frozen
at 80C until assayed.
POSTN assay
Serum POSTN was measured by a novel sandwich ELISA assay
(USCN, China) using a polyclonal antibody raised against the
fasciclin-1 like domain (amino acids 97e230) common to all iso-
forms. Brieﬂy, microtiter plates were pre-coated with the polyclonal
antibody as capture antibody. Serum samples or standards (recom-
binant fasciclin-1 likedomain of POSTN) are incubatedwith the same
polyclonal antibody but biotinylated for 2 h at 37C. After washing,
avidin conjugated to horseradish peroxidase (HRP) was added to
each microplate well and incubated for 1 h at 37C. After a washing
step, the substrate TMB is added to the well which reacts with HRP
and color is formed.After incubation, the reaction is stoppedwith the
addition of a sulphuric acid solution and the plate is read at 450 nm.
In our laboratory, the intra- and interassay coefﬁcients of vari-
ationwere lower than 10% and 15% respectively. The linearity of the
assay was assayed by testing four human serum samples with
appropriate concentration of human POSTN and their serial dilu-
tion. Themean recovery was 83%. The detection limit deﬁned as the
concentration of POSTN corresponding to the OD value of standard
0 þ 3 standard deviations was 29 ng/ml. The recovery of spiked
standards which was tested by adding two different concentrations
of standard into four different serum human samples presenting
with various levels of endogenous POSTN ranged from 91 to 103%
(see additional Figure 1 for antibody speciﬁcity).
Measurement of urinary CTX-II
For each woman, fasting ﬁrst-void morning urine samples were
collected and stored at 80C until measurement of urinary CTX-II,
a speciﬁc proteolytic fragment of type II collagen (CartiLaps; IDS).
Intra and interassay coefﬁcients of variation were less than 8% and
10%, respectively27.
Statistical analysis
All data were reported as mean ± SD unless otherwise speciﬁed.
Chi-square Wilcoxon tests and logistic regression were used to
compare characteristics between women with prevalent OA or not
before and after adjusting for confounding variables (age, treat-
ments and diseases, prevalent hand OA and prevalent lumbar spine
OA) which have been found signiﬁcantly different between groups
in the univariable analysis. Concerning the variable “treatments
and diseases”, sensitivity analysis was performed to identify the
effect of eliminating each of them individually upon the results.
Correlation analysis between serum POSTN and age or the variable
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Spearman test because the variables were not normally distributed.
We estimated the association between serum POSTN or urine
CTX-II, as continuous or categorized (per quartile) variables, and KL
progression using the “logistic regression” function in the STATA
software. Serum POSTN or urinary CTX-II values were tested as
independent variables and age, BMI, prevalent knee OA, prevalent
hand OA and prevalent lumbar spine OA as confounding variables.
As a proportion of participants had missing information for one of
the confounders [lumbar spine OA evaluated for 421 women (71%)]
we created a category for patients with missing values in order to
avoid ignoring these individuals in the multivariable analysis.
To distinguish progressors and non progressors, we developed
receiver operating characteristic (ROC) curve by the method of
cross validation. With this method, the entire dataset was used
both for the development and the validation models. The datawere
randomly divided into 10 mutually exclusive subsets of equal size
and ratio between progressors and non progressors. Themodel was
reﬁtted 10 times, omitting in turn one of the ten subsets. By this
way, the predicted values were calculated for the entire dataset. In a
ﬁnal step, the cross-validation estimate of the area under the ROC
curve was calculated using these ﬁtted values in a logistic regres-
sion model including age and POSTN.
All statistical analyses were performed using Stata 12 (StataCorp
LP, College Station, Texas, USA).Results
Baseline characteristics of women (Table I) and associations of
serum POSTN with other variables
Table I shows the baseline characteristics of the 594 women
included in this analysis who had data available for baseline POSTN
and CTX-II. Among them, 477 women (80.3%) were post meno-
pausal. POSTN and age were signiﬁcantly associated only in pre-
menopausal women (r ¼ þ0.31, P < 0.001). Serum POSTN was not
signiﬁcantly associated with body mass index (BMI) (P ¼ 0.99). We
found also no signiﬁcant association (P ¼ 0.27) between POSTN
levels and the variable grouping “treatments and diseases”
including treatments known to affect bone metabolism [hormone
replacement therapy (HRT, n ¼ 138), bisphosphonates (n ¼ 33),
Selective Estrogen Receptor Modulators (SERMs, n ¼ 8), cortico-
steroids (n ¼ 1)] and diseases known to affect POSTN metabolism
[breast cancer (n ¼ 13) and hyperparathyroidism (n ¼ 1)].Table I
Baseline characteristics of women included in this study. BMI ¼ body mass index,
KL ¼ Kellgren & Lawrence score, POSTN ¼ periostine, CTX-II ¼ a speciﬁc proteolytic
fragment of type II collagen, s ¼ serum, u ¼ urine
Variable Total population (n ¼ 594)
Age (yrs) 62.7 ± 11.2
Weight (kgr) 62.1 ± 10.2
Height (cm) 159.3 ± 6.1
BMI 24.5 ± 3.9
KL ¼ 0 (n, %) 397 (66.8%)
KL ¼ 1 (n, %) 114 (19.2%)
KL ¼ 2 (n,%) 59 (9.9%)
KL ¼ 3 (n,%) 16 (2.7%)
KL ¼ 4 (n,%) 8 (1.3%)
Incident knee OA (n,%) 62 (10.4%)
Progressors (KL score) (n,%) 82 (13.8%)
Prevalent lumbar spine OA (n,%) 351 (59.1%)
Prevalent hand OA (n,%) 188 (31.6%)
Prevalent hip OA (n,%) 57 (9.6%)
s-POSTN ng/ml 1170.0 ± 295.6
u-CTX-II ng/mmol creat. 184.4 ± 114.9Serum POSTN levels and prevalent knee OA (Table II)
Women with prevalent knee OA were older than women
without OA (P < 0.0001) had a higher BMI (P < 0.0001) and most of
them were postmenopausal (98%). After adjustment for age, BMI,
treatments and diseases, prevalent hand OA and prevalent lumbar
spine OA serum POSTN levels were moderately but signiﬁcantly
lower (7%) in the group of women suffering from OA than in the
511 womenwithout prevalent OA (P ¼ 0.002). Urinary CTX-II levels
were signiﬁcantly increased in the OA group (þ61%, P ¼ 0.001 after
adjusting for the same confounders).
When the analysis was focused on postmenopausal women,
who represented the majority of the population, the serum POSTN
levels were lower in women with prevalent OA than in women
without OA (P ¼ 0.002, after adjusting for the same confounders).
When the cut-off for prevalent OA was a KL score in 1, serum
POSTN levels were always slightly but signiﬁcantly lower (4.2%)
among the 197 womenwith prevalent OA compared to the women
without OA (P ¼ 0.013, after adjusting for the same confounders).
Moreover, urinary CTX-II levels were also signiﬁcantly increased in
this OA group (þ43.2%, P ¼ 0.008, after adjusting for the same
confounders).
Sensitivity analyses showed that serum POSTN was still signif-
icantly lower in women having prevalent OA compared to healthy
women after eliminating treatments or diseases individually:
bisphosphonates (P ¼ 0.003), SERMs (P ¼ 0.002), corticosteroids
(P ¼ 0.002), breast cancer (P ¼ 0.002), and hyperparathyroidism
(P ¼ 0.002). After eliminating women taking HRT (n ¼ 138), the
signiﬁcance was attenuated (P ¼ 0.06). Similar results were ob-
tained when the sensitivity analysis was restricted to post-
menopausal women (P < 0.01 for all except for HRT: P ¼ 0.08).
Serum POSTN levels and incidence/progression of knee OA (Table III
and Figs. 1 and 2)
Thewomenwho had a progression of knee KL at 4 years (n¼ 82)
were more likely to be older (P < 0.0001) had a higher BMI
(P ¼ 0.02) and most were postmenopausal (P < 0.0001). The pro-
gressors had more often prevalent lumbar spine OA (P ¼ 0.003),
prevalent knee OA (P ¼ 0.004) and prevalent hand OA (P ¼ 0.005)
than non progressors. When considered as a continuous variable,
serum POSTN levels in the group of progressors were not signiﬁ-
cantly decreased compared to non-progressors after adjustments
for age, BMI, prevalent knee OA, prevalent hand OA and prevalent
lumbar spine OA. Urinary CTX-II levels were signiﬁcantly higher
(þ33%, P ¼ 0.042) in knee OA women after the same adjustments .
In the group of KL progressors, 76 % (62 women) had a KL score
at baseline strictly lower than 2, meaning that this group represents
predominantly incident OA rather than progression of the disease
in the strict sense (Table III). When considered alone, these 62
women with incident knee OA had lower serum POSTN levels that
the other subjects although the difference did not reach statistical
signiﬁcance after adjustment for age (P ¼ 0.089).
When baseline POSTN levels were categorized in quartiles, there
was a signiﬁcant association between increased POSTN levels and
decreased incidence/progression [odds-ratio (95%CI): 0.79
(0.64e0.99, P ¼ 0.043) for each quartile increase of POSTN after
adjustment for age, BMI, prevalent knee OA, prevalent hand OA and
prevalent lumbar spine OA] (Fig. 1).
We found a similar association when we excluded premeno-
pausal women [odds-ratio 95%CI): 0.79 (0.64e0.99, P ¼ 0.04)].
Moreover, we assessed the performance of the multivariable
logistic regression model including age and POSTN levels to
discriminate between progressors and non progressors. The ROC
curve obtained by cross-validation showed an area under the curve
Table II
Baseline characteristics of womenwith and without prevalent OA (BMI ¼ body mass index). Baseline serum levels of POSTN and CTX-II in both groups (mean ± SD, s ¼ serum,
u ¼ urine). Prevalent knee OA was deﬁned by a KL score higher or equal in 2. Treatments known to affect bone metabolism [hormone replacement therapy (n ¼ 138),
bisphosphonates (n¼ 33), SERMs (n¼ 8) and corticosteroids (n¼ 1)] and diseases known to affect POSTNmetabolism [breast cancer (n¼ 13) and hyperparathyroidism (n¼ 1)]
Variables No prevalent knee
OA n ¼ 511
Prevalent knee
OA n ¼ 83 (KL  2)
P P*
Age (yrs) 60.4 ± 10 70.1 ± 9 <0.0001 e
Menopausal women (n, %) 399 (78%) 81 (98%) 0.001 e
BMI (kg. m2) 24.2 ± 3.8 26.6 ± 4.4 <0.0001 e
Prevalent lumbar spine (n,%) excluding
missing values
280 (54.8%) 71 (85.5%) 0.021 e
Missing values (n, % of the total) 167 (32.7%) 6 (7.2%)
Prevalent hip OA (n,%) 45 (8.8%) 12 (14.5%) 0.105 e
Prevalent hand OA (n,%) 141 (27.6%) 47 (56.6%) <0.0001 e
Treatments and diseases (n,%) 188 (36.8%) 16 (19.3%) 0.002 e
s-POSTN (ng/ml) 1181 ± 294 1101 ± 300 0.023 0.002
u-CTX-II (ng/mmol creat.) 173 ± 100 278 ± 154 <0.0001 0.001
* adjusted for age, BMI, treatments and diseases, prevalent hand OA and prevalent lumbar spine OA.
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(P ¼ 0.028).
Discussion
We observed that circulating levels of POSTN are lower in
women with prevalent knee OA and in OA progressors than in
controls. We also found a positive association between POSTN and
age in the group of pre-menopausal women only. Before the
menopause, the periosteal apposition compensated partially the
endocortical bone loss. With advancing age, the cortices become
thinner whereas the overall bone mass is unchanged because the
same amount of bone is distributed around a larger perimeter and
thus bone diameter increases28. This increase of bone diameter is
associated with an increase of the periosteum surface. Conse-
quently, we can hypothesize that the quantity of POSTN synthe-
sized may also increase with age in premenopausal women.
POSTN is a secreted protein synthesized by osteoblasts and
chondrocytes and in this way it could participate to the crosstalk
between subchondral bone and cartilage facilitated by alteration of
the tidemark in OA disease. Moreover, recent independent studies
in rats and in human showed that the POSTN gene is up-regulated
in the subchondral bone from OA cartilage10e12. Here, unexpect-
edly, we found that POSTN protein concentrations in serum were
signiﬁcantly decreased in women with prevalent OA and in pro-
gressors in the next four years. The reasons for the discrepancy
between gene expression at the joint tissue level and serumTable III
Baseline characteristics of progressors and non-progressors (mean ± SD, BMI ¼ body mas
the KL score at follow up 9. POSTN and CTX-II levels at baseline in the progressor and non
bone metabolism [hormone replacement therapy (n ¼ 138), bisphosphonates (n ¼ 33)
metabolism [breast cancer (n ¼ 13) and hyperparathyroidism (n ¼ 1)]
Variables NON progressors
n ¼ 512
Age (yrs) 61 ± 10
Menopausal women (n, %) 397 (78%)
BMI (kg. m2) 24.3 ± 3.9
Prevalent lumbar spine OA (n, %)
excluding missing values
279 (81%)
Missing values (n,% of the total) 176 (34.4%)
Prevalent knee OA (n,%) 63 (12%)
Prevalent hip OA (n,%) 48 (9%)
Prevalent hand OA (n,%) 151 (30%)
Treatments and diseases (n,%) 182 (35.5%)
s-POSTN (ng/ml) 1179 ± 295
u-CTX-II (ng/mmol creat.) 179 ± 109
* adjusted for age, BMI, prevalent knee OA, prevalent hand OA and prevalent lumbar spconcentration of POSTN are unclear but could be related to the
following factors.
The clearance of POSTN from the articular tissues to the serum is
unknown. It could undergo a degradation process leading to an
underestimation of its serum concentration. Similarly the structure
of the circulating forms of POSTN e particularly the level of
gamma-carboxylation that could interfere with the antibodies
recognition-is also not determined. It was recently showed that the
tertiary structure of the FAS-1 domains could be modiﬁed by the
binding of a ligand or post-translational modiﬁcation29 suggesting
that the epitope recognized by antibodies of the POSTN assay could
be hidden in some situations. Finally, although POSTN can exist in
different isoforms, the POSTN immunoassay has been developed to
recognize all of them.
Secondly, Ma et al. showed recently that the Wnt-b-catenin
signaling pathway has an anti-catabolic role in human chon-
drocytes30,31. The decreased serum levels of POSTN could lead to
an inhibition or an absence of stimulation of the Wnt-b-catenin
pathway, by the direct action of POSTN on this pathway or indi-
rectly via the inhibition of POSTN on the SOST expression16,32.
Consequently, the Wnt-b-catenin pathway may be not enough
stimulated to exert its anti-catabolic role. This hypothesis is sup-
ported by the signiﬁcant and concomitant increase of collagen
type II degradation e assessed with CTX-II measurement-in the
group of women suffering from OA at baseline suggesting that the
cartilage degradation increases when levels of serum POSTN
decrease.s index). Progressors are womenwith a KL score at follow up 13 strictly higher than
-progressor groups (mean ± SD, s ¼ serum, u ¼ urine). Treatments known to affect




67 ± 8 <0.0001 e
80 (98%) <0.0001 e
25.4 ± 3.9 0.02 e
72 (95%) 0.003 e
6 (7.3%)
20 (24%) 0.004 e
9 (11%) 0.39 e
37 (45%) 0.005 e
22 (26.8%) 0.12 e
1112 ± 293 0.059 0.073
238 ± 131 <0.0001 0.042
ine OA.
Fig. 1. Number (percentage) of KL progressors at 4 years according to quartiles of
serum POSTN at baseline. The odds-ratio per quartile is 0.79 (95% CI ¼ 0.64e0.99;
P ¼ 0.043) after adjustment for age, BMI, prevalent knee OA, prevalent hand OA and
prevalent lumbar spine OA.
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mechanical force due to the cartilage and bone alterations33.
Finally, it is also possible that the difference between gene
expression and protein levels could be due to alterations in tran-
scriptional, translation or post-translational processes.
Longitudinal studies investigating for a long period of time -4
years- the value of molecular markers in predicting incidence/
progression of joint damage are scarce18. Here, we found that for
each quartile increase in the levels of serum POSTN at baseline, the
odds-ratio of incidence/progression was signiﬁcantly reduced by
21% after adjustment for age, BMI, prevalent knee OA, prevalent
hand OA and prevalent lumbar spine OA. Simultaneously, urinary
CTX-II levels were signiﬁcantly increased among the progressors
compared to the non progressors (P ¼ 0.042 same adjustments).
The differences in serum POSTN between progressors and non
progressors are modest. However, we recently showed that even
such a small change of POSTN serum levels, comparable to those
highlighted in this study, can have a signiﬁcant impact on frac-
ture risk34. Moreover, the relationships between serum POSTN
and the risk of disease incidence/progression appear to be in an
opposite direction in osteoporosis and OA. Indeed, higher levels
of serum POSTN were associated with an increased risk of frac-
ture34 but a lower risk of radiological incidence/progression in
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Fig. 2. Receiver operating characteristic (ROC) curve of serum POSTN and age for
predicting OA incidence/progression over 4 years. Using a cross validation model, we
conducted a ROC analysis to evaluate the discriminating value of serum POSTN levels
and age to predict an increase of at least 1 KL grade over 4 years. The area under the
curve was 0.66 (95% CI ¼ 0.61e0.72, P ¼ 0.028).in our study for prevalent OA and progressors, may have a
sizeable effect on the metabolism of structural proteins, because
we observed a parallel increase of CTX-II levels. Moreover, POSTN
is involved in regulating the Wnt signaling pathway which is an
important regulator of both bone and joint metabolism16,32. We
also showed recently that POSTN is not only expressed in oste-
oblasts but also in osteoclasts from mouse long bones differen-
tiated in vitro35.
The prevalence of OA increases dramatically in women around
the age of 50 coinciding with the onset of menopause and sug-
gesting a link between OA and ovarian function with a protective
effect of estrogens. However when the analysis was restricted to
postmenopausal women who accounted for 80% of the population,
the relationship between POSTN and OA was not modiﬁed. When
each bone disease or treatment was individually excluded, the re-
sults were also virtually unaltered, except for HRT probably for lack
of statistical power.
Additional studies are needed to better understand the complex
role of POSTN in the maintenance of bone strength considering its
preferential localisation in the periosteumwhich is highly sensitive
to mechanical stimuli. Also, this protein being expressed both in
osteoblasts and osteoclasts, its respective roles in cartilage and
bone remain elusive. Nevertheless, the large overlap in serum
POSTN levels between progressors and non progressors and the
modest AUC (<0.7) of the ROC curve suggests that its clinical value
as a prognostic test is limited in the present stage of the assay
technique.
Our study has strengths and some limitations.We investigated for
the ﬁrst time the association between serum POSTN and prevalence
and incidence/progression of OA in a large and well characterized
population of women followed prospectively over a long period of
time. We veriﬁed that the loss of POSTN during long term storage is
very limited18. Because all samples were stored for an average of 10
years, if a loss of immunoreactivity has occurred this would affect
similarly samples fromOAcases and controls. Therefore, thepotential
long-term storage effect has probably limited impact on the inves-
tigated association. Prevalence of lumbar spine OA in our cohort was
high, but consistent with previously published data36,37. Moreover,
using Nevitt criteria38, we observed that 73% of women had symp-
tomatic lumbar spine OA. Finally, a single rheumatologist scored the
radiographs for knee OA. Consequently, it is difﬁcult to judge how
intra-observer variability might inﬂuence the data analysis.
The number of progressors was limited (n ¼ 82) and our results
need to be conﬁrmed by additional larger studies.
The assaywe used is believed to detect all isoforms of circulating
POSTN. However, we do not know which isoform(s) is/are the most
relevant to assess cartilage metabolism and if POSTN isoform(s)
expressed by cartilage is/are the same than POSTN isoform(s)
expressed by bone. Finally we investigated only predominantly
healthy women. Thus, these ﬁndings may not apply to men or
patients with a more severe OA.
In conclusion, lower serum POSTN levels are associated with
increased prevalence and incidence/progression of OA in women.
Themolecular mechanisms relating serum POSTN to OA prevalence
and incidence/progression remain to be further explored.
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